Animal testing persists as a standard part of drug development and safety screening, but the scientific, ethical, and economic case against it has grown substantially stronger in recent years. Roughly 96% of drugs that pass animal trials fail when tested in humans, and newer technologies are already outperforming animal models in key areas. Here’s a closer look at why many scientists, ethicists, and lawmakers argue the practice should end.
Animal Tests Fail to Predict Human Results
The most straightforward argument against animal testing is that it doesn’t work very well. In 2004, the FDA estimated that 92% of drugs passing animal tests failed to reach the market. More recent analysis puts that failure rate closer to 96%. The primary reasons: the drugs either don’t work in people or cause safety problems that animal tests completely missed.
About half of all drug failures in human clinical trials are due to toxic effects that showed up despite the drug being deemed safe in animals. The most common types of toxicity behind drug withdrawals in the U.S. and Europe are liver damage (21%), cardiovascular problems (16%), blood disorders (11%), neurological effects (9%), and cancer risk (8%). These aren’t rare edge cases. They represent a systemic inability of animal models to flag the dangers that matter most to human patients.
The biological reason is simple: humans and other species process drugs differently. The liver enzymes responsible for breaking down medications vary significantly between mice, rats, dogs, monkeys, and humans in terms of composition, expression levels, and activity. A mouse liver may neutralize a compound that proves devastating to a human liver, or vice versa. When researchers directly compared how well mouse models predicted outcomes for Alzheimer’s disease, sepsis, and acute respiratory distress syndrome, the results were described in one major review as “dismal.”
Better Technologies Already Exist
One of the strongest arguments for making animal testing illegal is that superior alternatives are no longer hypothetical. They’re here, and in several cases they already outperform animal models.
Organ-on-a-chip technology, which uses tiny devices lined with living human cells to mimic the function of organs like the liver, lung, and heart, is a leading example. A recent evaluation of nearly 800 human liver chips tested against a blinded set of over 27 drugs with known toxicity profiles achieved up to 87% sensitivity and 100% specificity. That means the chips caught most of the dangerous drugs and never mislabeled a safe drug as toxic. Animal models, by comparison, routinely miss liver toxicities that only appear in humans.
Artificial intelligence is also reshaping early drug discovery. AI-discovered drug molecules have shown an 80 to 90% success rate in Phase I clinical trials, substantially higher than the historical industry average. Phase II results so far are comparable to industry norms, though the sample size is still limited. These tools can screen millions of molecular candidates in a fraction of the time it takes to run a single animal study.
Even for basic skin and eye irritation testing, alternatives are proving their worth. When researchers compared synthetic human skin models against the traditional Draize test (which applies chemicals to rabbit skin or eyes), the synthetic models matched real-world human outcomes with 75 to 100% accuracy, while the Draize test managed only about 50%. A separate analysis found the Draize test would misidentify a serious irritant as a mild one between 10 and 39% of the time.
Oversight Systems Are Weak
In the United States, Institutional Animal Care and Use Committees (IACUCs) are supposed to ensure that animal experiments are necessary, not duplicative, and as humane as possible. In practice, these committees have deep structural problems.
U.S. law does not require committee members to have expertise in the specific research being reviewed or in non-animal methods that could replace animal use. Investigators must claim their study doesn’t duplicate previous research, but committee members aren’t required to verify that claim. Although researchers are expected to consider alternatives to painful procedures, they are not required to use them. And for animals not covered by the Animal Welfare Act (which excludes mice, rats, and birds, the vast majority of lab animals), consideration of alternatives to painful procedures isn’t required at all.
The majority of U.S. research institutions now allow a single committee member to approve research proposals through a system called Designated Member Review, bypassing full committee consideration. Committee members are often compensated by the same institution that benefits financially from the research, creating obvious conflicts of interest. A 2012 survey found that while 91% of committee members rated their own performance positively, only 74% of veterinarians on those committees felt members were adequately trained for the job.
The Legal Landscape Is Shifting
Governments around the world are already moving away from requiring animal testing, particularly for cosmetics. The European Union banned cosmetic animal testing in 2013. India, Israel, South Korea, Australia, and several other nations followed. Brazil enacted a nationwide ban effective July 31, 2025, expanding earlier regional laws in São Paulo and Rio de Janeiro to the federal level.
The shift is now reaching pharmaceutical regulation. The FDA Modernization Act 2.0, signed into U.S. law, removed the longstanding requirement that drugs must be tested on animals before human trials. The FDA has since announced plans to phase out animal testing requirements for monoclonal antibodies and other drugs, replacing them with AI-based toxicity models, cell-based assays, and organoid testing. FDA Commissioner Martin Makary called it “a paradigm shift in drug evaluation.” Companies submitting strong non-animal safety data may receive streamlined review, and the agency is launching pilot programs to test primarily non-animal testing strategies.
These legal changes reflect a growing recognition that mandating animal testing doesn’t just raise ethical concerns. It actively slows down drug development by requiring a step that fails to predict human outcomes the vast majority of the time.
The Scale of Animal Use
Precise global numbers are difficult to pin down because many countries don’t require comprehensive reporting, and the most commonly used species (mice, rats, and birds) are excluded from reporting requirements in the U.S. under the Animal Welfare Act. Switzerland, which does track usage carefully, reported 522,636 laboratory animals used in 2024 alone. Mice accounted for about 67% of that total, followed by birds (13%), rats (8%), and fish (6%). Estimates for global annual use range into the hundreds of millions when all species and all countries are included.
These animals experience procedures ranging from blood draws to surgeries, forced chemical exposure, and deliberate induction of diseases they would never naturally develop. The ethical weight of this becomes harder to justify as the scientific failure rate of the testing it supports becomes clearer.
The Economic Argument
Animal testing is expensive. Maintaining animal colonies requires specialized facilities, veterinary staff, and years-long study timelines. When roughly 88% of drugs that enter animal testing never even make it to human trials, and then the majority of those that do still fail, the financial waste is enormous. The pharmaceutical industry spends billions of dollars per approved drug, and a significant portion of that cost is absorbed by animal studies that produce misleading results.
Non-animal methods tend to be faster and more scalable. Organ chips can produce toxicity data in days or weeks rather than months. Computational models can screen thousands of compounds before a single physical test is run. Redirecting resources from animal facilities toward these technologies could both lower drug development costs and improve the quality of safety predictions reaching human patients.